secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYNAVAX TECHNOLOGIES CORP (—)
CIK:        0001029142
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001029142-25-000031
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Dynavax enters supply agreement with West for HEPLISAV-B stoppers; CFO also named principal accounting officer
--------------------------------------------------------------------------------

- Entered 4-year supply agreement with West Pharmaceutical Services for syringe stoppers for HEPLISAV-B, replacing 2016 agreement.
- Obligated to purchase certain volumes; pricing based on annual volume and subject to price index adjustments.
- Kelly MacDonald, current CFO, appointed as principal accounting officer effective February 13, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1029142/000102914225000031/0001029142-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1029142/000102914225000031/dvax-20250210.htm
  HTML page:      https://secwatch.observer/filing/0001029142-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer